[Goals and practical implementation of lipid therapy in coronary heart disease]
- PMID: 9303897
- DOI: 10.1007/BF03044350
[Goals and practical implementation of lipid therapy in coronary heart disease]
Abstract
In all patients with coronary heart disease a fasting lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides) should be obtained. Hyperlipidemias can then be classified as hypercholesterolemia (LDL cholesterol elevated), mixed hyperlipidemia (LDL cholesterol elevated, triglycerides elevated) and hypertriglyceridemia (triglycerides elevated). Primary goal of lipid intervention is a LDL cholesterol < 100 mg/dl, secondary goals are HDL cholesterol > 35 mg/dl and triglycerides < 200 mg/dl. These goals can be reached by dietary intervention alone (reduction in fat and modification of fat intake) or in combination with lipid lowering drugs. Monotherapy with HMG-CoA reductase inhibitors or combined therapy with bile acid sequestrants will allow a reduction in LDL cholesterol by more than 50%; in predominant hypertriglyceridemia fibrates or nicotinic acid will lower triglycerides and elevate HDL cholesterol.
Similar articles
-
Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.Ann Intern Med. 1996 Oct 1;125(7):529-40. doi: 10.7326/0003-4819-125-7-199610010-00001. Ann Intern Med. 1996. PMID: 8815751 Clinical Trial.
-
2017 Taiwan lipid guidelines for high risk patients.J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24. J Formos Med Assoc. 2017. PMID: 28242176 Review.
-
[Effects of lipid lowering measures on coronary perfusion].Z Kardiol. 1997;86 Suppl 1:43-55. Z Kardiol. 1997. PMID: 9173721 Review. German.
-
Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.Am J Cardiovasc Drugs. 2003;3(3):169-78. doi: 10.2165/00129784-200303030-00003. Am J Cardiovasc Drugs. 2003. PMID: 14727929 Review.
-
Achieving optimal lipid goals in patients with coronary artery disease.Am J Cardiol. 2011 Mar 15;107(6):886-90. doi: 10.1016/j.amjcard.2010.11.006. Epub 2011 Jan 19. Am J Cardiol. 2011. PMID: 21247526
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical